We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+4.31%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.43B
AUM Growth
+$292M
Cap. Flow
+$65.8M
Cap. Flow %
4.59%
Top 10 Hldgs %
64.89%
Holding
82
New
14
Increased
33
Reduced
12
Closed
20
Avg Time Held Equity + Options
1.2 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1.3 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
CYH icon
Community Health Systems
CYH
+$37.3M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$35M
3
AMRN icon
Amarin Corp
AMRN
+$19.9M
4
AMED icon
Amedisys
AMED
+$19.4M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$14.7M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$77.7M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$27.1M
3
NVST icon
Envista
NVST
+$21.6M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$17.9M
5
HLN icon
Haleon
HLN
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.06%
2 Miscellaneous 22.43%
3 Financials 0.95%
4 Communication Services 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$168M 11.7%
+410,000
New +$164M
2023 Q1
0 quarters
NTRA icon
2
Natera
NTRA
$58.3B
$157M 10.92%
2,819,770
+133,811
+5% +$6.42M
2022 Q2
3 quarters
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$487B
$144M 10.07%
+450,000
New +$133M
2023 Q1
0 quarters
GSK icon
4
GSK
GSK
$98.2B
$134M 9.34%
3,731,499
+241,042
+7% +$8.43M
2018 Q1
20 quarters
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$89.4M 6.23%
819,124
-245,322
-23% -$27.1M
2020 Q2
11 quarters
TEVA icon
6
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$54.8M 3.82%
6,194,572
+1,481,975
+31% +$14.7M
2020 Q3
10 quarters
UTHR icon
7
United Therapeutics
UTHR
$23.2B
$49.7M 3.47%
222,107
-10,680
-5% -$2.63M
2020 Q2
11 quarters
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.22B
$46.7M 3.25%
2,209,057
+588,344
+36% +$14.6M
2022 Q2
3 quarters
CYH icon
9
Community Health Systems
CYH
$422M
$44.5M 3.1%
9,082,305
+7,080,311
+354% +$37.3M
2020 Q4
9 quarters
BIIB icon
10
Biogen
BIIB
$34.8B
$42.8M 2.98%
153,774
+16,426
+12% +$4.55M
2021 Q4
5 quarters
ILMN icon
11
Illumina
ILMN
$40.5B
$39.7M 2.77%
175,312
+31,323
+22% +$6.41M
2022 Q1
4 quarters
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.05B
$37.7M 2.63%
4,520,724
+3,640,237
+413% +$35M
2022 Q4
1 quarter
CTLT icon
13
DELISTED
CATALENT, INC.
CTLT
$37.7M 2.63%
573,609
-118,068
-17% -$7.3M
2022 Q4
1 quarter
DHR icon
14
Danaher
DHR
$163B
$37.5M 2.62%
167,717
-15,663
-9% -$3.56M
2018 Q3
18 quarters
CLDX icon
15
Celldex Therapeutics
CLDX
$2.27B
$24.8M 1.73%
689,676
+130,902
+23% +$5.65M
2021 Q4
5 quarters
AMRN icon
16
Amarin Corp
AMRN
$244M
$21.9M 1.53%
730,638
+566,432
+345% +$19.9M
2018 Q1
20 quarters
CNC icon
17
Centene
CNC
$34.8B
$18.2M 1.27%
288,426
+73,865
+34% +$5.24M
2021 Q1
8 quarters
AMED icon
18
DELISTED
Amedisys
AMED
$16.5M 1.15%
+224,263
New +$19.4M
2023 Q1
0 quarters
ICLR icon
19
Icon
ICLR
$13.5B
$16.4M 1.14%
76,788
+10,095
+15% +$2.25M
2021 Q3
6 quarters
AVTR icon
20
Avantor
AVTR
$10.9B
$15.2M 1.06%
717,614
+117,414
+20% +$2.68M
2020 Q4
9 quarters
MCRB icon
21
Seres Therapeutics
MCRB
$25.4M
$14.4M 1%
126,833
+16,783
+15% +$1.82M
2022 Q3
2 quarters
TECH icon
22
Bio-Techne
TECH
$11.4B
$14M 0.98%
188,659
+172,024
+1,034% +$13.3M
2022 Q4
1 quarter
VERA icon
23
Vera Therapeutics
VERA
$2.06B
$13.9M 0.97%
1,788,529
+1,377,221
+335% +$10.6M
2022 Q3
2 quarters
ITCI icon
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.8M 0.83%
+218,726
New +$10.6M
2023 Q1
0 quarters
EHTH icon
25
eHealth
EHTH
$19.4M
$11.6M 0.81%
+1,234,283
New +$9.7M
2023 Q1
0 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Eversept Partners held 82 positions worth $1.43B, up 26% from $1.14B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Eversept Partners deployed $65.8M of net new capital in Q1 2023, opening 14 new positions and adding to 33 existing holdings. Its largest new stake was Amedisys: 224,263 shares worth $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $27.1M trimmed.

  • Eversept Partners's largest Q1 2023 buy was Amedisys: 224,263 shares worth $16.5M.
  • Eversept Partners added most to Community Health Systems in Q1 2023, an estimated $37.3M increase.
  • Eversept Partners's biggest Q1 2023 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $27.1M.
  • Eversept Partners fully exited Sanofi in Q1 2023, selling an estimated $77.7M.
  • Eversept Partners's ten largest holdings make up 65% of its $1.43B portfolio in Q1 2023.
  • Eversept Partners opened 14 new positions and closed 20 in Q1 2023.
  • Eversept Partners's portfolio value rose 26% quarter-over-quarter to $1.43B.

Based on Eversept Partners's 13F filing for Q1 2023, filed 15 May 2023.